Oridonin induces apoptosis and reverses drug resistance in cisplatin resistant human gastric cancer cells

He,Zhongwei; Xiao,Xiangling; Li,Shan; Guo,Yang; Huang,Qiuyue; Shi,Xin; Wang,Xiaobo; Liu,Ying

doi:10.3892/ol.2017.6421

Oridonin induces apoptosis and reverses drug resistance in cisplatin resistant human gastric cancer cells

Authors:
- Zhongwei He
- Xiangling Xiao
- Shan Li
- Yang Guo
- Qiuyue Huang
- Xin Shi
- Xiaobo Wang
- Ying Liu
View Affiliations

Affiliations: School of Basic Medical Sciences, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China
Published online on: June 19, 2017 https://doi.org/10.3892/ol.2017.6421
Pages: 2499-2504

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer is the third most frequent cause of cancer‑associated mortality and almost all patients who respond initially to cisplatin (DDP) later develop drug resistance, indicating multi‑drug resistance (MDR) is an essential aspect of the failure of treatment. The natural diterpenoid component Oridonin (Ori) has exhibited efficient inhibition in several types of human cancer. However, the effect and potential mechanism of Ori‑reversed MDR in human gastric cancer has not been fully elucidated. In the present study, it was found that Ori significantly suppressed DDP-resistant human SGC7901/DDP cell proliferation, growth and colony formation, causing increased caspase‑dependent apoptosis, decreased expression of P-glycoprotein (P‑gp), encoded by the MDR gene, multi‑drug resistance‑associated protein (MRP1), and cyclin D1. SGC7901/DDP cells were cultured with different groups of drugs (Ori, DDP alone, or the combination of Ori and DDP). The drug sensitivity, cell apoptosis and effects on MDR were detected by MTT assay and western blot analysis. The results revealed that Ori is able to reverse the DDP resistance and has a clear synergistic effect with DDP in SGC7901/DDP cells by decreasing the levels of P‑gp, MRP1, cyclin D1 and cancerous inhibitor of protein phosphatase 2A. Thus, Ori may be a novel effective candidate to treat DDP‑resistant human gastric cancer cells.

View Figures

View References

1	Niccolai E, Taddei A, Prisco D and Amedei A: Gastric cancer and the epoch of immunotherapy approaches. World J Gastroenterol. 21:5778–5793. 2015.PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
3	Yang X, Cai H, Liang Y, Chen L, Wang X, Si R, Qu K, Jiang Z, Ma B, Miao C, et al: Inhibition of c-Myc by let-7b mimic reverses mutidrug resistance in gastric cancer cells. Oncol Rep. 33:1723–1730. 2015.PubMed/NCBI
4	Ni P, Xu W, Zhang Y, Chen Q, Li A, Wang S, Xu S and Zhou J: TXNL1 induces apoptosis in cisplatin resistant human gastric cancer cell lines. Current Cancer Drug Targets. 14:850–859. 2015. View Article : Google Scholar : PubMed/NCBI
5	Fan K, Fan D, Cheng LF and Li C: Expression of multidrug resistance-related markers in gastric cancer. Anticancer Res. 20:4809–4814. 2000.PubMed/NCBI
6	Hong L, Piao Y, Han Y, Wang J, Zhang X, Du Y, Cao S, Qiao T, Chen Z and Fan D: Zinc ribbon domain-containing 1 (ZNRD1) mediates multidrug resistance of leukemia cells through regulation of P-glycoprotein and Bcl-2. Mol Cancer Ther. 4:1936–1942. 2005. View Article : Google Scholar : PubMed/NCBI
7	Owona BA and Schluesener HJ: Molecular insight in the multifunctional effects of oridonin. Drugs R D. 15:233–244. 2015. View Article : Google Scholar : PubMed/NCBI
8	Zhou GB, Kang H, Wang L, Gao L, Liu P, Xie J, Zhang FX, Weng XQ, Shen ZX, Chen J, et al: Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. Blood. 109:3441–3450. 2007. View Article : Google Scholar : PubMed/NCBI
9	Xu B, Shen W, Liu X, Zhang T, Ren J, Fan Y and Xu J: Oridonin inhibits BxPC-3 cell growth through cell apoptosis. Acta Biochim Biophys Sin (Shanghai). 47:164–173. 2015. View Article : Google Scholar : PubMed/NCBI
10	Li Y, Wang Y, Wang S, Gao Y, Zhang X and Lu C: Oridonin phosphate-induced autophagy effectively enhances cell apoptosis of human breast cancer cells. Med Oncol. 32:3652015. View Article : Google Scholar : PubMed/NCBI
11	Chen RY, Xu B, Chen SF, Chen SS, Zhang T, Ren J and Xu J: Effect of oridonin-mediated hallmark changes on inflammatory pathways in human pancreatic cancer (BxPC-3) cells. World J Gastroenterol. 20:14895–14903. 2014. View Article : Google Scholar : PubMed/NCBI
12	Wang YY, Lv YF, Lu L and Cai L: Oridonin inhibits mTOR signaling and the growth of lung cancer tumors. Anticancer Drugs. 25:1192–1200. 2014. View Article : Google Scholar : PubMed/NCBI
13	Zhao Z and Chen Y: Oridonin, a promising antitumor natural product in the chemotherapy of hematological malignancies. Curr Pharm Biotechnol. 15:1083–1092. 2014. View Article : Google Scholar : PubMed/NCBI
14	Liu Y, Cao W, Zhang B, Liu YQ, Wang ZY, Wu YP, Yu XJ, Zhang XD, Ming PH, Zhou GB and Huang L: The natural compound magnolol inhibits invasion and exhibits potential in human breast cancer therapy. Sci Rep. 3:30982013. View Article : Google Scholar : PubMed/NCBI
15	Cao W, Liu Y, Zhang R, Zhang B, Wang T, Zhu X, Mei L, Chen H, Zhang H, Ming P and Huang L: Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells. Sci Rep. 5:84772015. View Article : Google Scholar : PubMed/NCBI
16	Chou CC, Yang JS, Lu HF, Ip SW, Lo C, Wu CC, Lin JP, Tang NY, Chung JG, Chou MJ, et al: Quercetin-mediated cell cycle arrest and apoptosis involving activation of a caspase cascade through the mitochondrial pathway in human breast cancer MCF-7 cells. Arch Pharm Res. 33:1181–1191. 2010. View Article : Google Scholar : PubMed/NCBI
17	Radisavljevic Z: AKT as locus of cancer multidrug resistance and fragility. J Cell Physiol. 228:671–674. 2013. View Article : Google Scholar : PubMed/NCBI
18	Liu H, Gu Y, Wang H, Yin J, Zheng G, Zhang Z, Lu M, Wang C and He Z: Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer. Oncotarget. 6:14913–14925. 2015. View Article : Google Scholar : PubMed/NCBI
19	Khanna A and Pimanda JE: Clinical significance of cancerous inhibitor of protein phosphatase 2A in human cancers. Int J Cancer. 138:525–532. 2016. View Article : Google Scholar : PubMed/NCBI
20	Zhang JL, Liu XZ, Wang PY, Chen GW, Jiang Y, Qiao SK, Zhu J, Wang X, Pan YS and Liu YC: Targeting HCCR expression resensitizes gastric cancer cells to chemotherapy via down-regulating the activation of STAT3. Sci Rep. 6:241962016. View Article : Google Scholar : PubMed/NCBI
21	Simonian PL, Grillot DA and Nuñez G: Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood. 90:1208–1216. 1997.PubMed/NCBI
22	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
23	Nicholson DW: Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ. 6:1028–1042. 1999. View Article : Google Scholar : PubMed/NCBI
24	Johnstone RW, Ruefli AA and Lowe SW: Apoptosis: A link between cancer genetics and chemotherapy. Cell. 108:153–164. 2002. View Article : Google Scholar : PubMed/NCBI
25	Zhao Z, Wang J, Tang J, Liu X, Zhong Q, Wang F, Hu W, Yuan Z, Nie C and Wei Y: JNK- and Akt-mediated Puma expression in the apoptosis of cisplatin-resistant ovarian cancer cells. Biochem J. 444:291–301. 2012. View Article : Google Scholar : PubMed/NCBI
26	Hasegawa M, Ishiguro K, Ando T and Goto H: Geranylgeranylacetone attenuates cisplatin-induced reductions in cell viability by suppressing the elevation of intracellular p53 content without heat shock protein induction. Nagoya J Med Sci. 74:123–131. 2012.PubMed/NCBI
27	Alcantara LM, Kim J, Moraes CB, Franco CH, Franzoi KD, Lee S, Freitas-Junior LH and Ayong LS: Chemosensitization potential of P-glycoprotein inhibitors in malaria parasites. Exp Parasitol. 134:235–243. 2013. View Article : Google Scholar : PubMed/NCBI
28	Luo L, Sun YJ, Yang L, Huang S and Wu YJ: Avermectin induces P-glycoprotein expression in S2 cells via the calcium/calmodulin/NF-kappaB pathway. Chem Biol Interact. 203:430–439. 2013. View Article : Google Scholar : PubMed/NCBI
29	Ying L, Zu-An Z, Qing-Hua L, Qing-Yan K, Lei L, Tao C and Yong-Ping W: RAD001 can reverse drug resistance of SGC7901/DDP cells. Tumour Biol. 35:9171–9177. 2014. View Article : Google Scholar : PubMed/NCBI
30	Kornmann M, Arber N and Korc M: Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. J Clin Invest. 101:344–352. 1998. View Article : Google Scholar : PubMed/NCBI